Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	64
Overall Study	STARTED	Atacicept 25 mg	66
Overall Study	STARTED	Atacicept 75 mg	62
Overall Study	STARTED	Atacicept 150 mg	64
Overall Study	Treated	Placebo	62
Overall Study	Treated	Atacicept 25 mg	66
Overall Study	Treated	Atacicept 75 mg	62
Overall Study	Treated	Atacicept 150 mg	64
Overall Study	COMPLETED	Placebo	50
Overall Study	COMPLETED	Atacicept 25 mg	59
Overall Study	COMPLETED	Atacicept 75 mg	49
Overall Study	COMPLETED	Atacicept 150 mg	60
Overall Study	NOT COMPLETED	Placebo	14
Overall Study	NOT COMPLETED	Atacicept 25 mg	7
Overall Study	NOT COMPLETED	Atacicept 75 mg	13
Overall Study	NOT COMPLETED	Atacicept 150 mg	4

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00430495/flow